Viewing nowCombinationEmpagliflozin/Metformin Sustained-Release Tablets 10/1000 mg
Metformin Hydrochloride 1000mg · Empagliflozin 10mg
Tablet · Prescription medication · Combination
Dongwha Pharmaceutical Co., Ltd.

MFDS item code 202500992 · Approved 2025.04.24 · Insurance code 642707820
Improvement of glycemic control in adults with type 2 diabetes
This medication is used to improve blood sugar control in adult patients with type 2 diabetes, in conjunction with diet and exercise. It is particularly administered to patients whose blood sugar is not adequately controlled, and in case of cardiovascular disease, specialist instructions should be followed. This medication effectively aids in controlling blood sugar and helps manage diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg and the patient's current dose of metformin. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment may be needed based on renal function, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, discontinue this medicine immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.
This medication is used for the treatment of diabetes and helps in controlling blood sugar. When taking this medication, there is a risk of a rare side effect known as severe lactic acidosis, so symptoms must be closely monitored. Lactic acidosis is a condition where there is an excessive buildup of lactic acid in the body, which can be very dangerous. Additionally, caution is required when taken with insulin or sulfonylurea medications due to the risk of hypoglycemia. Patients with impaired kidney function, acute kidney problems, serious infections, congestive heart failure, acute myocardial infarction, or other specific health conditions should not take this medication. The use of iodine contrast agents before and after examinations requires temporary cessation of this medication, and it should be restarted only after kidney function has been confirmed as normal. Women who are pregnant or might become pregnant, patients with liver dysfunction, and patients who are in very poor nutritional status are also advised not to use this medication. During treatment, side effects such as hypoglycemia, urinary tract infections, genitourinary infections, increased urination, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, constipation, reduced and deficient vitamin B12 levels, taste disturbances, itching, rashes, abnormal liver function tests, hepatitis, urinary difficulties, interstitial nephritis, thirst, increased serum lipids, increased blood creatinine/decreased glomerular filtration rate, increased hematocrit, weight loss, lumbar pain, headaches, dizziness, insomnia, nausea, and gastritis may occur, so symptoms should be closely monitored. Especially for elderly patients aged 75 and older, there is an increased risk of fluid loss, so careful administration is required. This medication should be swallowed whole without breaking or chewing, and the tablet shell may pass in the stool, which is normal. Additionally, alcohol consumption may increase the risk of lactic acidosis, so alcohol should be avoided during treatment. Regular monitoring of kidney function and serum vitamin B12 levels during the use of this medication is recommended. If any abnormal symptoms or discomfort occur, consultation with a physician should be sought immediately, and prompt treatment is necessary in case of emergency.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.
Pale pink, bilaterally convex, oval-shaped sustained-release film-coated tablet
30 tablets per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Empagliflozin 10mg
Tablet · Prescription medication · Combination
Dongwha Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.